Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

5.690 -0.170 (-2.90%)
Streaming Delayed Price Updated: 3:52 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NextCure, Inc. - Common Stock

< Previous 1 2 3 4 Next >
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From NextCure
Via GlobeNewswire
NextCure (NXTC) Q2 Loss Widens 71%
Via The Motley Fool
Topics Intellectual Property
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed. 
Via Benzinga
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment
NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility. 
Via Stocktwits
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease
NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical data for NC605. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Thursday's after hours session: top gainers and losers
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
Monday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline
The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. 
Via Stocktwits
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
From NextCure
Via GlobeNewswire
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
From NextCure
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's pre-market session.
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
From NextCure
Via GlobeNewswire
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe
Via Stocktwits
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
From NextCure
Via GlobeNewswire
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences 
From NextCure
Via GlobeNewswire
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS